Head to Head Comparison: PainReform (PRFX) and Its Peers

PainReform (NASDAQ:PRFX – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare PainReform to similar businesses based on the strength of its dividends, analyst recommendations, risk, profitability, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for PainReform and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PainReform 1 0 0 0 1.00
PainReform Competitors 7859 13811 25856 1041 2.41

As a group, “Pharmaceuticals” companies have a potential upside of 30.32%. Given PainReform’s competitors stronger consensus rating and higher possible upside, analysts plainly believe PainReform has less favorable growth aspects than its competitors.

Profitability

This table compares PainReform and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PainReform N/A N/A N/A
PainReform Competitors -2,391.71% -206.07% -14.88%

Valuation & Earnings

This table compares PainReform and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
PainReform $20,000.00 -$5.02 million -0.00
PainReform Competitors $3.54 billion $3.17 billion 556.78

PainReform’s competitors have higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

37.3% of PainReform shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

PainReform has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, PainReform’s competitors have a beta of -0.05, suggesting that their average share price is 105% less volatile than the S&P 500.

Summary

PainReform competitors beat PainReform on 7 of the 13 factors compared.

PainReform Company Profile

(Get Free Report)

PainReform Ltd. is an Israel-based specialty pharmaceutical company developing treatments for postoperative pain. Its lead candidate, PRF-110, is an extended-release formulation of the local anesthetic ropivacaine designed for administration at a surgical site to provide pain relief after surgery. The company’s development work has focused on evaluating PRF-110 for postoperative pain management in procedures including bunion surgery and hernia repair. PainReform’s research centers on drug-delivery approaches intended to extend the effect of local anesthetics.

Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.